Recent Updates
Recently added Catalysts
NKTR Positive Sentiment

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025 Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it...

Monday, June 23, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Nektar Therapeutics has announced that it will host an investor call to review top-line data from the 16-week induction period of its Phase 2b REZOLVE-AD clinical trial. This trial examines rezpegaldesleukin, a T-cell proliferator, for treating moderate-to-severe atopic dermatitis. The event is scheduled for June 24, 2025, and details will be available through a morning press release and on the company's website. A replay of the presentation will also be accessible for at least 30 days post-event.
Price reaction · baseline $8.51 (2025-06-20 close) · 2 other NKTR headline(s) in the window, move may be shared
day 0 close
+12.1%
day 1
+187.3%
day 3 · peak
+248.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Nektar is set to announce top-line data from a significant clinical trial.
  • The study focuses on a novel treatment for moderate-to-severe atopic dermatitis.
  • The upcoming investor call demonstrates Nektar's commitment to transparency with stakeholders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
10.2%
average across 4 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
Rezpegaldesleukin
Phase 3 · Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

SAN FRANCISCO , June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it will host an investor call and live webcast to review top-line data from the 16-week induction period in the ongoing global Phase 2b REZOLVE-AD clinical trial of investigational rezpegaldesleukin, a regulatory T-cell (Treg) proliferator, for moderate-to-severe atopic dermatitis on Tuesday, June 24, 2025 at 8:15am ET / 5:15am PT .
The data will be provided in a morning press release and presented during the webcast. Details on how to access the live webcast of the call will be available in the morning press release and on the Nektar website at www.nektar.com . A replay of the webcast will be available for at least 30 days following the event.
About Nektar Therapeutics

Frequently Asked Questions

When is the Nektar Therapeutics investor call?

The investor call is on Tuesday, June 24, 2025, at 8:15 AM ET.

What is the purpose of the investor call?

The call will review top-line data from the Phase 2b REZOLVE-AD trial.

How can I access the webcast?

Access details will be in a morning press release and on the Nektar website.

What does rezpegaldesleukin target?

Rezpegaldesleukin is a Treg proliferator for atopic dermatitis.

How long will the webcast replay be available?

The webcast replay will be accessible for at least 30 days post-event.

ShareAdd on Google
Tags: NKTR Viatris Investor Conferences Healthcare Nektar Therapeutics Rezpegaldesleukin atopic dermatitis clinical trial immunology
Last updated: Jun 23, 2025

Biotech snapshot

Cash runway
$1023M liquidity · $25M/mo burn
~40 mo
Minimal dilution risk
Lead asset
RezpegaldesleukinPhase 3
Moderate-to-Severe Atopic Dermatitis →

Catalyst track record

+186%
best trade around NKTR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for NKTR.

See every catalyst's timing & PoA →